Sign In
Buy BCAB
$3.29
-0.0900 (-2.66%)
At Close: Jul 31, 2026
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody thera
BioAtla: A Buried ADC Concern Gets Some New Life In 2024
10:03am, Thursday, 02'nd May 2024
BioAtla is a biotech company focused on developing conditionally activated biologics for cancer therapy. Their approach is an attempt to harness the Warburg effect to conditionally activate immunologi
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
04:35pm, Wednesday, 24'th Apr 2024
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the
BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript
07:21pm, Tuesday, 26'th Mar 2024
BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
04:01pm, Tuesday, 26'th Mar 2024
SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
08:00am, Tuesday, 19'th Mar 2024
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
08:00am, Thursday, 07'th Mar 2024
SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 20'th Dec 2023
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types
08:00am, Wednesday, 13'th Dec 2023
Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher doses Ongoing Phase 2 clinical study of monotherapy and i
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023
08:00am, Wednesday, 06'th Dec 2023
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
08:00am, Tuesday, 05'th Dec 2023
Results from the Phase 2 BA3011 clinical non-small cell lung cancer (NSCLC) study demonstrated promising clinical benefits in heavily pre-treated non-squamous histology patients across key endpoints
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
08:00am, Thursday, 30'th Nov 2023
SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
08:00am, Tuesday, 28'th Nov 2023
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript
05:38am, Sunday, 12'th Nov 2023
BioAtla, Inc. (NASDAQ:BCAB ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors, LLC Jay Short - Chairman, Chief Exec
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
04:01pm, Tuesday, 07'th Nov 2023
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
